Summary
Recently, compounds having pure antiestrogenic activity have become available. In this study, we examined the activity of the new steroidal antiestrogen EM-170 (N-n-butyl, N-methyl-11-(16′α-chloro-3′,17′α-dihydroxy-estra-1′,3′,5′-(10′)-trien-7′α-yl) undecanamide) on the growth of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma stimulated by treatment with estrone (E1), a steroid known to play an important role as precursor of 17β-estradiol (E2), especially in postmenopausal women. Twenty-five days after ovariectomy (OVX), tumor volume in control OVX animals decreased to 51.4 ± 11% of the initial volume; treatment with E1, administered by Silastic implants, stimulated tumor growth to 179 ± 21%. Treatment with the antiestrogen EM-170 at a dose of 200 µg (twice daily) not only completely reversed the stimulatory effect of E1, but also inhibited tumor growth to 30.5 ± 9.6%, an effect that is 41% (P < 0.01 vs OVX control) greater than that of ovariectomy alone. At a relatively low dose of 40 µg (twice daily), 20 days of treatment with EM-170 reversed by 55% the stimulatory effect of E1 (1.0 µg, subcutaneously, twice daily) on tumor growth in OVX animals. On the other hand, the antiestrogen also induced a significant inhibitory effect on 17β-hydroxysteroid dehydrogenase (17β-HSD) activity in the DMBA-induced mammary tumors, an effect that is in agreement with the marked reduction caused by the same treatment on tumor estradiol (E2) levels in E1-treated OVX animals. The present data show that the new steroidal antiestrogen EM-170 exerts a potent inhibitory effectin vivo on E1-stimulated growth of DMBA-induced mammary tumors, an effect that is probably mediated by both its antiestrogenic activity at the receptor level and its inhibitory effect on 17β-HSD, thus inhibiting local E2 formation and facilitating the action of the antiestrogen at the receptor level.
References
Huggins C, Grand LC, Brillantes FP: Mammary cancer induced by a single feeding of polynuclear hydrocarbons, and its suppression. Nature 189: 204–207, 1961
Asselin J, Labrie F, Kelly PA, Philibert D, Raynaud JP: Specific progesterone receptors in dimethylbenz(a)anthracene (DMBA)-induced mammary tumors. Steroids 27: 395–404, 1976
Labrie F, Kelly PA, Asselin J, Raynaud JP: Potent inhibitory activity of a new antiestrogen, RU16117, on the development and growth of DMBA-induced rat mammary adenocarcinoma. In: Band G, Israel L (eds) Breast Cancer, A Multidisciplinary Approach. Recent Results in Cancer Research. Springer-Verlag, New York, vol 57, 1976, pp 109–120
Asselin J, Labrie F: Effects of estradiol and prolactin on steroid receptor levels in 7,12-dimethylbenz(a)anthracene-induced mammary tumors and uterus in the rat. J Steroid Biochem 9: 1079–1082, 1977
Spinola PG, Marchetti B, Labrie F: Adrenal steroids stimulate growth and progesterone receptor levels in rat uterus and DMBA-induced mammary tumors. Breast Cancer Res Treat 8: 241–248, 1986
Dickson RB, Lippman ME: Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev 8: 29–43, 1987
Dowsett M, Goss PE, Powles TJ, Hutchinson G, Brodie AMH, Jeffcoate SL, Coombes RC: Use of the aromatase inhibitor 4-hydroxyandrostenedione in post-menopausal breast cancer: optimization of therapeutic doses and route. Cancer Res 47: 1957–1961, 1987
Miller WR: Fundamental research leading to improved endocrine therapy for breast cancer. J Steroid Biochem 27: 477–485, 1987
Furr BJ, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25: 127–205, 1984
McNab MW, Tallarida RJ, Joseph R: An evaluation of tamoxifen as a partial agonist by classical receptor theory, an explanation of the dual action of tamoxifen. Eur J Pharmacol 103: 321–326, 1984
Poulin R, Mérand Y, Poirier D, Lévesque C, Dufour JM, Labrie F: Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen and ICI164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells. Breast Cancer Res Treat 14: 65–76, 1989
Bucourt R, Vignau M, Torelli V, Richard-Foy H, Geynet C, Secco-Milet C, Redeuil HG, Baulieu EE: New biospecific absorbents for the purification of estradiol receptor. J Biol Chem 253: 8221–8228, 1978
Wakeling AE, Bowler J: Steroidal pure antiestrogens. J Endocrinol 112: R7-R10, 1987
Dauvois S, Geng CS, Lévesque C, Mérand Y, Labrie F: Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of ZR-75-1 breast tumors in athymic mice. Cancer Res 51: 3131–3135, 1991
de Launoit Y, Dauvois S, Dufour M, Simard J, Labrie F: Inhibition of cell cycle kinetics and proliferation by the androgen 5α-dihydrotestosterone and antiestrogen N-n-butyl-N-methyl-11-(16′α-chloro-3′,17β-dihydroxy-estra-1′,3′,5′-(10′)-triene-7′α-yl) undecanamide in human breast cancer ZR-75-1 cells. Cancer Res 51: 2797–2802, 1991
Lévesque C, Mérand Y, Dufour JM, Labrie C, Labrie F: Synthesis and biological activity of new halo-steroidal antiestrogens. J Med Chem 34: 1624–1630, 1991
Labrie C, Martel C, Dufour JM, Lévesque C, Mérand Y, Labrie F: Novel compounds inhibit estrogen formation and action. Cancer Res 52: 610–615, 1992
Dauvois S, Labrie F: Androstenedione and androst-5-ene-3β,17β-diol stimulate DMBA-induced rat mammary tumors- role of aromatase. Breast Cancer Res Treat 13: 61–69, 1989
Dauvois S, Li S, Martel C, Labrie F: Inhibitory effect of androgens on DMBA-induced mammary carcinoma in the rat. Breast Cancer Res Treat 14: 299–306, 1989
Dauvois S, Spinola PG, Labrie F: Additive inhibitory effects of bromocriptine (CB-154) and medroxyprogesterone acetate (MPA) on dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat. Eur J Cancer Clin Oncol 25: 891–897, 1989
Bradford M: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254, 1976
Bélanger A, Caron S, Picard V: Simultaneous radioimmunoassay of progestins, androgens, and estrogens in adult rat testis. J Steroid Biochem 13: 185–190, 1980
Bélanger A, Labrie F, Angeli A: Unconjugated and glucuronide steroid levels in human breast cyst fluid. In: Angeli A, Bradlow HL, Chasalow FI, Gogliotti L (eds) Biochemistry of breast cyst fluid. Correlation with breast cancer risk. Ann NY Acad Sci, vol. 586, pp 93–100, 1990
Kramer CY: Extension of multiple range tests to group means with unique numbers of replications. Biometrics 12: 307–310, 1956
McGuire WL, Carbone PP, Sears ME, Escher GC: Estrogen receptors in human breast cancer: an overview. In: McGuire WL, Carbone PP, Vollmer EP (eds) Estrogen receptors in human breast cancer. Raven Press, New York, 1975, pp 1–7
Poulin R, Labrie F: Stimulation of cell proliferation and estrogenic response by adrenal C19-Δ5-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res 46: 4933–4937, 1986
Henderson BE, Ross R, Bernstein L: Estrogens as a cause of human cancer: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 48: 246–253, 1988
Poulin R, Simard J, Labrie C, Petitclerc L, Dumont M, Lagacé L, Labrie F: Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line. Endocrinology 125: 392–399, 1989
Poulin R, Baker D, Poirier D, Labrie F: Multiple actions of synthetic ‘progestins’ on the growth of ZR-75-1 human breast cancer cells: anin vitro model for the simultaneous assay of androgen, progestin, estrogen and glucocorticoid agonistic and antagonistic activities of compounds. Breast Cancer Res Treat 17: 197–210, 1991
Siiteri PK, MacDonald PC: The role of extraglandular estrogen in human endocrinology. In: Freiger SR, Astwood EB, Greep RO (eds) Handbook of Physiology, Section 7. The American Physiological Society, New York, 1973, pp 615–619
Labrie F, Simard J, Luu-The V, Trudel C, Martel C, Labrie C, Zhao HF, Rhéaume E, Couët J, Breton N: Expression of 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase (3β-HSD) and 17β-hydroxysteroid dehydrogenase (17β-HSD) in adipose tissue. Int J Obes 15: 91–99, 1991
Milewich L, Garcia RL, Gerrity L: 17β-hydroxysteroid oxidoreductase: an ubiquitous enzyme. Interconversion of estrone and estradiol-17β in BALB/c mouse tissues. Metabolism 34: 938–944, 1985
Luu-The V, Labrie C, Simard J, Lachance Y, Zhao HF, Couët J, Leblanc G, Labrie F: Structure of two in tandem human 17β-hydroxysteroid dehydrogenase genes. Mol Endocrinol 4: 268–275, 1990
Labrie F: Intracrinology. Mol Cell Endocrinol 78: C113-C118, 1991
Prudhomme JF, Malet C, Gompel A, Lalardrie JP, Ochoa C, Boue A, Mauvais-Jarvis P, Kuttenn F: 17β-hydroxysteroid dehydrogenase activity in human breast epithelial cell and fibroblast culture. Endocrinology 114: 1483–1489, 1984
Tait GH, Newton CJ, Reed MJ, James VH: Multiple forms of 17β-hydroxysteroid oxidoreductase in human breast tissue. Mol Endocrinol 2: 71–80, 1989
Thériault C, Labrie F: Hormonal regulation of estradiol 17β-hydroxysteroid dehydrogenase activity in the ZR-75-1 human breast cancer cell line. Ann NY Acad Sci 595: 419–421, 1990
Couture P, Thériault C, Simard J, Labrie F: Androgen receptor-mediated stimulation of 17β-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Endocrinology 132: 179–185, 1993
Bonney RC, Reed MJ, Davidson K, Beranek PA, James VHT: The relationship between 17β-hydroxysteroid dehydrogenase activity and estrogen concentrations in human breast tumors and in normal breast tissue. Clin Endocrinol 19: 727–739, 1983
Vermeulen A, Deslypere JP, Paridaens R, Leclercq G, Roy F, Heuson JC: Aromatase, 17β-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur J Cancer Clin Oncol 22: 515–525, 1986
King RJB, Panattoni M, Gordon J, Baker R: The metabolism of steroids by tissue from normal and neoplastic rat breast. J Endocrinol 33: 127–132, 1965
King RJB, Gordon J, Helfenstein JE: The metabolism of testosterone by tissue from normal and neoplastic rat breast. J Endocrinol 29: 103–110, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Labrie, F., Li, S., Labrie, C. et al. Inhibitory effect of a steroidal antiestrogen (EM-170) on estrone-stimulated growth of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Breast Cancer Res Tr 33, 237–244 (1995). https://doi.org/10.1007/BF00665948
Issue Date:
DOI: https://doi.org/10.1007/BF00665948